Cases of accidental and deliberate overdosage with oral therapy have been reported. At plasma concentrations of up to 5 to 6 times the maximum therapeutic levels, there are unlikely to be any symptoms other than nausea, vomiting and dizziness. In massive overdose, 10 to 20 times the maximum therapeutic levels, there may be serious CNS depression or coma with muscular hypotonia, hyporeflexia, miosis, impaired respiratory function, metabolic acidosis. A favourable outcome is usual, however some deaths have occurred following massive overdose.
The symptoms may however be variable and seizures have been reported in the presence of very high plasma levels. Cases of intracranial hypertension related to cerebral oedema have been reported. A number of deaths have occurred following large overdoses.
Hospital management of overdose includes induced vomiting, gastric lavage, assisted ventilation and other supportive measures. Haemodialysis and haemoperfusion have been used successfully. Intravenous naloxone has also been used sometimes in association with activated charcoal given orally.
-
- Active liver disease.
- Personal or family history of severe hepatic dysfunction, especially drug related.
- Porphyria.
- Patients with known urea cycle disorders.
Valproate is contraindicated in patients known to have mitochondrial disorders caused by mutations in the nuclear gene encoding the mitochondrial enzyme polymerase γ (POLG), e.g. Alpers-Huttenlocher Syndrome, and in children under two years of age who are suspected of having a POLG-related disorder.
None known
Frequency categories are defined using the following convention:
Very common (>1/10)
Common (>1/100 to <1/10)
Uncommon (>1/1,000 to <1/100)
Rare (>1/10,000 to <1/1,000)
Very rare (<1/10,000)
Not known (cannot be estimated from the available data)
Congenital, familial and genetic disorders
Congenital malformations and developmental disorders.
| Neoplasms benign, malignant and unspecified (incl. cysts and polyps) | |
| Rare: | myelodysplastic syndrome |
| Hepato-biliary disorders | |
| Common: | liver injury |
| Not known: | severe liver damage, including hepatic failure sometimes resulting in fatalities |
| Gastro-intestinal disorders | |
| Very common: | nausea |
| Common: | vomiting, gingival disorder, (mainly gingival hyperplasia), stomatitis, gastralgia, diarrhoea. The above three adverse events frequently occur at the start of the treatment, but usually disappearing after a few days without discontinuing treatment. These problems can usually be overcome by taking Valnar® with or after food. |
| Uncommon: | pancreatitis, sometimes lethal |
| Psychiatric disorders | |
| Common: | confusional state, aggression*, agitation*, disturbance in attention* |
| Rare: | abnormal behaviour*, psychomotor hyperactivity*, learning disorder* |
| *These ADRs are principally observed in the paediatric population. Nervous system disorders: | |
| Very common: | tremor |
| Common: | extrapyramidal disorder, stupor*, somnolence, convulsion*, memory impairment, headache, nystagmus |
| Uncommon: | coma*, encephalopathy, lethargy* (see below), reversible parkinsonism, ataxia, paresthesia. |
| Rare: | reversible dementia associated with reversible cerebral atrophy, cognitive disorder. |
Sedation has been reported occasionally, usually when in combination with other anticonvulsants. In monotherapy it occurred early in treatment on rare occasions and is usually transient.
*Rare cases of lethargy occasionally progressing to stupor, sometimes with associated hallucinations or convulsions have been reported. Encephalopathy and coma have uncommonly been observed. These cases have often been associated with too high a starting dose or too rapid a dose escalation or concomitant use of other anticonvulsants, notably phenobarbital or topiramate. They have usually been reversible on withdrawal of treatment or reduction of dosage.
An increase in alertness may occur; this is generally beneficial but occasionally aggression, hyperactivity and behavioural deterioration have been reported.
| Endocrine disorders | |
| Uncommon: | Syndrome of Inappropriate Secretion of ADH (SIADH), hyperandrogenism (hirsutism, virilism, acne, male pattern alopecia, and/or androgen increased) |
| Rare: | hypothyroidism |
| Metabolism and nutrition disorders | |
| Common: | hyponatraemia |
| Rare: | hyperammonaemia* , obesity |
*Cases of isolated and moderate hyperammonaemia without change in liver function tests may occur, are usually transient and should not cause treatment discontinuation. However, they may present clinically as vomiting, ataxia, and increasing clouding of consciousness. Should these symptoms occur Valnar® should be discontinued.
Hyperammonaemia associated with neurological symptoms has also been reported. In such cases further investigations should be considered.
| Blood and lymphatic system disorders | |
| Common: | anaemia, thrombocytopenia |
| Uncommon: | pancytopenia, leucopenia |
| The blood picture returned to normal when the drug was discontinued. | |
| Rare: | bone marrow failure, including pure red cell aplasia, agranulocytosis, anaemia macrocytic, macrocytosis. |
Isolated findings of a reduction in blood fibrinogen and/or an increase in prothrombin time have been reported, usually without associated clinical signs and particularly with high doses (Valnar® has an inhibitory effect on the second phase of platelet aggregation).).).
| Skin and subcutaneous tissue disorders | |
| Common: | hypersensitivity, transient hair loss, which may sometimes be dose-related. Regrowth normally begins within 6 months, although the hair may become more curly than previously. nail and nail bed disorders |
| Uncommon: | angioedema, rash |
| Rare: | toxic epidermal necrolysis, Stevens-Johnson syndrome, erythema multiforme, Drug Rash with Eosinophilia and Systemic Symptoms (DRESS) syndrome. |
| Reproductive system and breast disorders | |
| Common: | dysmenorrhea |
| Uncommon: | amenorrhea |
| Rare: | male infertility, polycystic ovaries |
| Very rare: | gynaecomastia |
| Vascular disorders | |
| Common: | haemorrhage |
| Uncommon: | vasculitis |
| Ear and labyrinth disorders | |
| Common: | deafness, a cause and effect relationship has not been established |
| Renal and urinary disorders | |
| Rare: | enuresis, reversible Fanconi syndrome (a defect in proximal renal tubular function giving rise to glycosuria, amino aciduria, phosphaturia, and uricosuria) associated with Valnar® therapy, but the mode of action is as yet unclear. |
| General disorders and administration site conditions | |
| Uncommon: | non-severe oedema peripheral |
| Musculoskeletal and connective tissue disorders | |
| Uncommon: | bone mineral density decreased, osteopenia, osteoporosis and fractures in patients on long-term therapy with Valnar®. The mechanism by which Valnar® affects bone metabolism has not been identified. |
| Rare: | systemic lupus erythematosus |
| Respiratory, thoracic and mediastinal disorders | |
| Uncommon: | pleural effusion |
| Investigations | |
| Common: | weight increased* |
| Rare: | coagulation factors decreased (at least one), abnormal coagulation tests (such as prothrombin time prolonged, activated partial thromboplastin time prolonged, thrombin time prolonged, INR prolonged). |
*Weight increase should be carefully monitored since it is a factor for polycystic ovary syndrome.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system (see details below).
Yellow Card Scheme
Website: www.mhra.gov.uk/yellowcard
Testicular atrophy, degeneration of the vas deferens and inadequate spermatogenesis as well as changes to the lungs and prostate gland have been observed in chronic toxicity studies with high oral dosages (250 mg/kg in rats and 90 mg/kg in the dog).
Mutagenicity tests in bacteria, rats and mice yielded no evidence of mutagenic potential.
Long-term studies have been conducted in rats and mice. At very high doses, the rate of subcutaneous fibrosarcomas was increased in male rats. Animal studies have shown valproic acid to be teratogenic.
Sodium valproate is used in the:
- treatment of all forms of epilepsy.
- treatment of manic episode in bipolar disorder when lithium is contraindicated or not tolerated. The continuation of treatment after manic episode could be considered in patients who have responded to sodium valproate for acute mania.
Pharmacotherapeutic Group: Fatty acid derivatives
ATC code: N03AG01
The mode of action of valproic acid is not fully understood but may involve an elevation of gamma-amino butyric acid levels in the brain.
In certain in-vitro studies, it was reported that sodium valproate could stimulate HIV replication, but studies on peripheral blood mononuclear cells from HIV-infected subjects show that sodium valproate does not have a mitogen-like effect on inducing HIV replication. Indeed, the effect of sodium valproate on HIV replication ex-vivo is highly variable, modest in quantity, appears to be unrelated to the dose and has not been documented in man.
The increased expression of drug efflux transporters at the blood-brain barrier can results in lower concentrations of their respective substrate, i. e. the active substance, in the brain compared to its free concentration in plasma, and thereby reduce the concentration of antiepileptics at the site of action. This can lead to pharmacoresistance and thus to the development of a treatment-resistant status epilepticus or treatment-resistant epilepsy. However, in vitro data suggest that sodium valproate is not a substrate for transporters such as ATP-binding cassette (ABC) transporters (e. g. P-glycoprotein (Pgp)) or multidrug resistance-associated proteins (MRP1, MRP2 and MRP5). The development of pharmacoresistance against valproate by these transporters is therefore considered unlikely.
With peroral administration 90-100 % of the dose is rapidly absorbed.
Maximal plasma concentration is achieved with Valnar® within 6.5 ± 3.3 hours. The half-life is 12-16 h in most patients but can in exceptional cases be considerably lower. Impaired renal function prolongs the half-life. In infants under 2 months the half-life can be prolonged up to 60 hours but in older children it is the same as in adults.
Steady-state concentration is normally achieved after treatment in 3-5 days. A satisfactory effect is most often achieved at 50-100 µg/mL, but the patient's overall situation must be considered.
The relation between the dose and effect, and between plasma concentrations and effect, has not been fully clarified.
The cerebrospinal fluid concentration is up to 10 % of the plasma concentration. About 90 % of sodium valproate is bound to plasma protein (mainly to albumin), which may entail a risk of clinically significant interactions with other antiepileptics, primarily phenytoin. Protein binding decreases at higher dosages. Plasma protein binding is lower in elderly patients and in patients with kidney or liver dysfunction. In one study, elevated levels of the free drug (8.5 % up to more than 20 %) were observed in patients with significantly reduced renal function.
However, if hypoproteinaemia is present, the total concentration of valproic acid (free and protein-bound substance) can be essentially unchanged, although it may also be reduced due to the increased metabolism of the free portion.
Sodium valproate is metabolised to a great extent and is excreted in the urine as conjugated metabolites. Sodium valproate crosses the placental barrier and concentrations of foetal plasma are comparable to those in the mother.
Valproic acid passes into breast milk but is not likely to influence the child when therapeutic doses are used.
Suicidal ideation and behaviour have been reported in patients treated with antiepileptic agents in several indications. A meta-analysis of randomised placebo controlled trials of antiepileptic drugs has also shown a small increased risk of suicidal ideation and behaviour. The mechanism of this risk is not known and the available data do not exclude the possibility of an increased risk for sodium valproate.
Therefore patients should be monitored for signs of suicidal ideation and behaviours and appropriate treatment should be considered. Patients (and caregivers of patients) should be advised to seek medical advice should signs of suicidal ideation or behaviour emerge.
Although there is no specific evidence of sudden recurrence of underlying symptoms following withdrawal of valproate, discontinuation should normally only be done under the supervision of a specialist in a gradual manner. This is due to the possibility of sudden alterations in plasma concentrations giving rise to a recurrence of symptoms.
NICE has advised that generic switching of valproate preparations is not normally recommended due to the clinical implications of possible variations in plasma concentrations.
The concomitant use of sodium valproate and carbapenem is not recommended.
Aggravated convulsions:
As with other antiepileptic drugs, some patients may experience, instead of an improvement, a reversible worsening of convulsion frequency and severity (including status epilepticus), or the onset of new types of convulsions with valproate. In case of aggravated convulsions, the patients should be advised to consult their physician immediately.
Hepatic dysfunction
Conditions of occurrence
Severe liver damage, including hepatic failure sometimes resulting in fatalities, has been very rarely reported. Experience in epilepsy has indicated that patients most at risk, especially in cases of multiple anticonvulsants therapy, are infants and in particular young children under the age of 3 and those with severe seizure disorders, organic brain disease, and (or) congenital metabolic or degenerative disease associated with mental retardation. After the age of 3, the incidence of occurrence is significantly reduced and progressively decreases with age. The concomitant use of salicylates should be avoided in children under 3 due to the risk liver toxicity. Additionally, salicylates should not be used in children under 16 years of age (see aspirin/salicylate product information on Reye's syndrome).
Monotherapy is recommended in children under the age of 3 years when prescribing Valnar®, but the potential benefit of Valnar® should be weighed against the risk of liver damage or pancreatitis in such patients prior to initiation of therapy.
In most cases, such liver damage occurred during the first 6 months of therapy, the period of maximum risk being 2 - 12 weeks.
Suggestive signs
Clinical symptoms are essential for early diagnosis. In particular the following conditions, which may precede jaundice, should be taken into consideration, especially in patients at risk (see above: Conditions of occurrence):
- non-specific symptoms, usually of sudden onset, such as asthenia, malaise, anorexia, lethargy, oedema and drowsiness, which are sometimes associated with repeated vomiting and abdominal pain.
- in patients with epilepsy, recurrence of seizures
These are an indication for immediate withdrawal of the drug.
Patients (or their carers), should be instructed to report immediately any such signs to a physician should they occur. Investigations including clinical examination and biological assessment of liver function should be undertaken immediately.
Detection
Liver function should be measured before and then periodically monitored during the first 6 months of therapy, especially in those who seem at risk, and those with a prior history of liver disease. Amongst usual investigations, tests which reflect protein synthesis, particularly prothrombin rate, are most relevant. Confirmation of an abnormally low prothrombin rate, particularly in association with other biological abnormalities (significant decreases in fibrinogen and coagulation factors; increased bilirubin level and raised transaminases) require cessation of Valnar® therapy.
As a matter of precaution and in case they are taken concomitantly salicylates should also be discontinued since they employ the same metabolic pathway.
As with most antiepileptic drugs, increased liver enzymes are common, particularly at the beginning of therapy; they are also transient.
More extensive biological investigations (including prothrombin rate) are recommended in these patients; a reduction in dosage may be considered when appropriate and tests should be repeated as necessary.
Pancreatitis
Pancreatitis, which may be severe and result in fatalities, has been very rarely reported. Patients experiencing nausea, vomiting or acute abdominal pain should have a prompt medical evaluation (including measurement of serum amylase).
Young children are at particular risk; this risk decreases with increasing age. Severe seizures and severe neurological impairment with combination anticonvulsant therapy may be risk factors. Hepatic failure with pancreatitis increases the risk of fatal outcome. In case of pancreatitis, Valnar® should be discontinued.
Haematological
Blood tests (blood cell count, including platelet count, bleeding time and coagulation tests) are recommended prior to initiation of therapy or before surgery, and in case of spontaneous bruising or bleeding..
Renal insufficiency
In patients with renal insufficiency, it may be necessary to decrease dosage. As monitoring of plasma concentrations may be misleading, dosage should be adjusted according to clinical monitoring.
Systemic lupus erythematosus
Although immune disorders have only rarely been noted during the use of sodium valproate, the potential benefit of Valnar® should be weighed against its potential risk in patients with systemic lupus erythematosus.
Hyperammonaemia
When urea cycle enzymatic deficiency is suspected, metabolic investigations should be performed prior to treatment because of risk of hyperammonaemia with sodium valproate.
Weight gain
Sodium valproate very commonly causes weight gain, which may be marked and progressive. Patients should be warned of the risk of weight gain at the initiation of therapy and appropriate strategies should be adopted to minimise it.
| Female children/Female adolescents/Women of childbearing potential/Pregnancy: Valnar® should not be used in female children, in female adolescents, in women of childbearing potential and pregnant women unless alternative treatments are ineffective or not tolerated because of its high teratogenic potential and risk of developmental disorders in infants exposed in utero to valproate. The benefit and risk should be carefully reconsidered at regular treatment reviews, at puberty and urgently when a woman of childbearing potential treated with Valnar® plans a pregnancy or if she becomes pregnant. Women of childbearing potential must use effective contraception during treatment and be informed of the risks associated with the use of Valnar® during pregnancy. The prescriber must ensure that the patient is provided with comprehensive information on the risks alongside relevant materials, such as a patient information booklet, to support her understanding of the risks. In particular the prescriber must ensure the patient understands: - The nature and the magnitude of the risks of exposure during pregnancy, in particular the teratogenic risks and the risks of developmental disorders. - The need to use effective contraception. - The need for regular review of treatment. - The need to rapidly consult her physician if she is thinking of becoming pregnant or there is a possibility of pregnancy. In women planning to become pregnant all efforts should be made to switch to appropriate alternative treatment prior to conception, if possible. Valproate therapy should only be continued after a reassessment of the benefits and risks of the treatment with valproate for the patient by a physician experienced in the management of epilepsy or bipolar disorder. |
Patients with known or suspected mitochondrial disease
Valproate may trigger or worsen clinical signs of underlying mitochondrial diseases caused by mutations of mitochondrial DNA as well as the nuclear encoded POLG gene. In particular, valproate-induced acute liver failure and liver-related deaths have been reported at a higher rate in patients with hereditary neurometabolic syndromes caused by mutations in the gene for the mitochondrial enzyme polymerase γ (POLG),e.g. Alpers-Huttenlocher Syndrome.
POLG-related disorders should be suspected in patients with a family history or suggestive symptoms of a POLG-related disorder, including but not limited to unexplained encephalopathy, refractory epilepsy (focal, myoclonic), status epilepticus at presentation, developmental delays, psychomotor regression, axonal sensorimotor neuropathy, myopathy, cerebellar ataxia, ophthalmoplegia, or complicated migraine with occipital aura. POLG mutation testing should be performed in accordance with current clinical practice for the diagnostic evaluation of such disorders.
Diabetic patients
Sodium valproate is eliminated mainly through the kidneys, partly in the form of ketone bodies: this may give false positive results in the urine testing of possible diabetics.
Alcohol
Alcohol intake is not recommended during treatment with valproate.
Granules in stools
The prolonged-release granules are surrounded by an indigestible cellulose shell through which the sodium valproate is released and these shells will be seen as white residues in the stools of the patient. There are no safety issues concerning such residues.
Use of Valnar® may provide seizure control such that the patient may be eligible to hold a driving licence.
At the start of treatment with sodium valproate, at higher dosages or with a combination of other centrally acting drugs, reaction time may be altered to an extent that affects the ability to drive or to operate machinery, irrespective of the effect on the primary disease being treated. Patients should be warned of the risk of transient drowsiness. This is especially the case when taken during anticonvulsant polytherapy, concomitant use of benzodiazepines or in combination with alcohol.
Female children, female adolescents, women of childbearing potential and pregnant women
Valnar® should be initiated and supervised by a specialist experienced in the management of epilepsy or bipolar disorder. Treatment should only be initiated if other treatments are ineffective or not tolerated and the benefit and risk should be carefully reconsidered at regular treatment reviews. Preferably Valnar® should be prescribed as monotherapy and at the lowest effective dose, if possible as a prolonged release formulation to avoid high peak plasma concentrations. The daily dose should be divided into at least two single doses.
Posology
Treatment in all forms of epilepsy:
Dosage requirements vary according to age and body weight and should be adjusted individually to achieve adequate seizure control. The daily dosage should be given in 1 - 2 single doses.
Monotherapy
Usual requirements are as follows:
Adults
Dosage should start at 600mg daily increasing by 150-300mg at three day intervals until control is achieved. This is generally within the dosage range of 1000mg to 2000mg per day i.e. 20-30mg/kg body weight daily. Where adequate control is not achieved within this range the dose may be further increased to a maximum of 2500mg per day.
Children over 20kg
Initial dosage should be 300mg/day increasing until control is achieved. This is usually within the range 20-30mg/kg body weight per day. Where adequate control is not achieved within this range, the dose may be increased to 35 mg/kg body weight per day.
Children under 20kg
20mg/kg body weight per day; in severe cases this may be increased up to 40mg/kg/day.
Elderly
Care should be taken when adjusting dosage in the elderly since the pharmacokinetics of sodium valproate are modified. The volume of distribution is increased in the elderly and because of decreased binding to serum albumin, the proportion of free drug is increased. This will affect the clinical interpretation of plasma valproic acid levels. Dosage should be determined by seizure control.
In patients with renal insufficiency
It may be necessary to decrease dosage. Dosage should be adjusted according to clinical monitoring since monitoring of plasma concentrations may be misleading.
In patients with hepatic insufficiency
Salicylates should not be used concomitantly with sodium valproate since they employ the same metabolic pathway.
Liver dysfunction, including hepatic failure resulting in fatalities, has occurred in patients whose treatment included valproic acid.
Salicylates should not be used in children under 16 years (see aspirin/salicylate product information on Reye's syndrome). In addition in conjunction with sodium valproate, concomitant use in children under 3 years can increase the risk of liver toxicity.
Combined Therapy
When starting Valnar® in patients already on anticonvulsants, these should be tapered slowly; initiation of Valnar® treatment should then be gradual, with target dose being reached after about 2 weeks. In certain cases it may be necessary to raise the dose by 5 to 10mg/kg/day when used in combination with liver enzyme inducing drugs such as phenytoin, phenobarbital and carbamazepine. Once known enzyme inducers have been withdrawn it may be possible to maintain seizure control on a reduced dose of Valnar®.
When barbiturates are being administered concomitantly and particularly if sedation is observed (particularly in children) the dosage of barbiturate should be reduced.
N.B. In children requiring doses higher than 40 mg/kg/day clinical chemistry and haematological parameters should be monitored.
Optimum dosage is mainly determined by seizure control and routine measurement of plasma levels is unnecessary. However, a method for measurement of plasma levels is available and may be helpful where there is poor control or side effects are suspected.
Manic episodes in bipolar disorder
Adults
The daily dosage should be established and controlled individually by the treating physician. The initial recommended daily dose is 750 mg. In addition, in clinical trials a starting dose of 20 mg sodium valproate/kg body weight has also shown an acceptable safety profile. Prolonged-release formulations can be given once or twice daily. The dose should be increased as rapidly as possible to achieve the lowest therapeutic dose which produces the desired clinical effect. The daily dose should be adapted to the clinical response to establish the lowest effective dose for the individual patient. The mean daily dose usually ranges between 1,000 and 2,000 mg sodium valproate. Patients receiving daily doses higher than 45 mg/kg/day body weight should be carefully monitored.
Continuation of treatment of manic episodes in bipolar disorder should be adapted individually using the lowest effective dose.
Children and adolescents
The safety and efficacy of Valnar® for the treatment of manic episodes in bipolar disorder have not been evaluated in patients aged less than 18 years.
Method of administration
For oral administration.
The contents of the sachet may be sprinkled or stirred into soft food or drinks and swallowed immediately without chewing, or crushing the prolonged- release granules. The food or drink should be cold or at room temperature. A mixture of the granules with liquid or soft food should not be stored for future use. If the contents of the sachet are taken in a drink, as some granules may stick to the glass after the drink has been finished, the glass should be rinsed with a small amount of water and this water swallowed as well. The prolonged-release granules should not be given in babies' bottles as they can block the teat.
When changing from sodium valproate enteric coated tablets to Valnar® it is recommended to keep the same daily dose.
No special requirements
